CAR T cell therapy for autoimmune diseases
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests a new type of cell therapy (CAR T cells) that targets certain immune cells to treat autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, and systemic sclerosis. It may help people whose disease is not well controlled with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed autoimmune disease such as rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis with active symptoms despite treatment.
- Your blood counts and organ function (kidney, liver, blood clotting) must meet certain minimum levels.
- You cannot have had a major organ or stem cell transplant.
- You cannot have an active infection (including hepatitis, HIV, tuberculosis, or other serious infections).
- You cannot be pregnant, breastfeeding, or planning pregnancy within 2 years of treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses your own engineered immune cells (CAR-T cells) to treat severe autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis that haven't improved with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This trial tests a new type of cell therapy (SCAR02) that targets two proteins on immune cells to help calm down overactive autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis. It may be an option if standard treatments haven't worked well enough.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.